Generic ERYTHROMYCIN STEARATE INN entry, drug patent and freedom to operate

Sponsor	Phase
Chr Hansen A/S	N/A
Chr Hansen	N/A
Ryerson University	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ETHRIL 500	erythromycin stearate	TABLET;ORAL	061605-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Purepac Pharm	ERYTHROMYCIN STEARATE	erythromycin stearate	TABLET;ORAL	061743-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Azurity	ERYTHROCIN STEARATE	erythromycin stearate	TABLET;ORAL	060359-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bristol	BRISTAMYCIN	erythromycin stearate	TABLET;ORAL	061304-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Erythromycin stearate, an antibiotic in the macrolide class, faces a mature market characterized by established generic competition and consistent but modest demand. Its financial trajectory is primarily influenced by healthcare policy, evolving antimicrobial resistance patterns, and the cost-effectiveness of generic manufacturing.

What is Erythromycin Stearate and its Therapeutic Applications?

Erythromycin stearate is an oral ester prodrug of erythromycin. It is designed to be more stable in the acidic environment of the stomach, improving patient compliance by reducing gastrointestinal side effects. Upon absorption, it is hydrolyzed to active erythromycin, which exerts its antibacterial effect by inhibiting protein synthesis in susceptible microorganisms.

Erythromycin stearate is indicated for the treatment of a range of bacterial infections. These include:

Respiratory tract infections: Such as pneumonia, bronchitis, and pharyngitis caused by susceptible organisms like Streptococcus pneumoniae and Haemophilus influenzae.
Skin and soft tissue infections: Including cellulitis, erysipelas, and impetigo, often caused by Staphylococcus aureus and Streptococcus pyogenes.
Sexually transmitted diseases: Specifically, uncomplicated urethral, cervical, or rectal infections caused by Chlamydia trachomatis.
Diphtheria: As an adjunct to antitoxin in the treatment of diphtheria, and for prophylaxis in exposed individuals.
Legionnaires' disease: Caused by Legionella pneumophila.
Mycoplasmal pneumonia: Also known as "walking pneumonia."

The drug's spectrum of activity encompasses Gram-positive bacteria and some Gram-negative bacteria, as well as atypical organisms. However, resistance has emerged in many common pathogens, limiting its empirical use in certain settings.

What are the Key Market Drivers for Erythromycin Stearate?

The market for erythromycin stearate is driven by several factors, primarily linked to its established therapeutic role and its generic availability.

1. Persistent Demand for Common Infections: Erythromycin stearate remains a treatment option for specific bacterial infections where it maintains efficacy and where cost is a significant consideration. Its role in treating mild to moderate respiratory and skin infections, particularly in regions with limited access to newer, more expensive antibiotics, ensures a baseline demand. Global incidence rates of conditions like strep throat and uncomplicated pneumonia contribute to this consistent need.

2. Cost-Effectiveness of Generic Manufacturing: As a widely off-patent drug, erythromycin stearate benefits from a highly competitive generic market. Manufacturing processes are well-established, and raw material costs are generally stable. This cost-effectiveness makes it an attractive option for healthcare systems, pharmacies, and patients globally, especially in emerging markets or for individuals with high-deductible insurance plans. The average wholesale price (AWP) for erythromycin stearate formulations typically ranges from $0.10 to $0.50 per tablet or capsule, significantly lower than many newer macrolides [1].

3. Formulary Placement and Guideline Recommendations: In many healthcare systems and hospital formularies, erythromycin stearate is retained for specific indications due to its historical efficacy, safety profile, and cost. Clinical practice guidelines, while evolving, may still recommend it for certain susceptible infections, particularly in situations where resistance to other macrolides is a concern or when broader-spectrum agents are deemed unnecessary or too costly [2].

4. Use in Specific Patient Populations: Erythromycin stearate is sometimes preferred for certain patient populations, such as pregnant women, where the safety profile of other antibiotics might be a concern. Its established safety record, when used appropriately, contributes to its continued prescription in these niches.

5. Prophylactic Use: In some limited scenarios, erythromycin stearate may be used prophylactically. For instance, it has been historically used for the prevention of ophthalmia neonatorum, although silver sulfadiazine and topical erythromycin ointment are now more common [3]. Its role in diphtheria prophylaxis also contributes to a small but persistent demand.

What are the Major Market Restraints for Erythromycin Stearate?

Despite its established uses, several factors limit the growth and market share of erythromycin stearate.

1. Increasing Antibiotic Resistance: The most significant restraint is the widespread and growing resistance to erythromycin and other macrolides. Pathogens like Streptococcus pneumoniae, Staphylococcus aureus, and Haemophilus influenzae have developed resistance mechanisms, including ribosomal modification (erm genes) and efflux pumps (mef genes) [4]. This reduces the drug's effectiveness, leading to treatment failures and necessitating the use of alternative, often broader-spectrum and more expensive, antibiotics. This trend is a major driver for the decline in its use in empirical therapy.

2. Availability of Newer Macrolides and Alternative Antibiotics: The pharmaceutical industry has developed newer macrolide antibiotics, such as azithromycin and clarithromycin, which offer improved pharmacokinetic profiles (longer half-lives, better tissue penetration), broader spectrums of activity, and often improved tolerability compared to erythromycin. Furthermore, a wide array of alternative antibiotic classes, including beta-lactams, fluoroquinolones, and tetracyclines, are available for treating bacterial infections, often with better efficacy against resistant strains [5]. These newer agents capture a larger share of the market, especially for more serious infections.

3. Gastrointestinal Side Effects: While erythromycin stearate is a prodrug designed to improve tolerability, it can still cause gastrointestinal side effects, including nausea, vomiting, abdominal pain, and diarrhea. These side effects can lead to poor patient compliance and physician reluctance to prescribe, particularly when alternative agents with better tolerability profiles are available.

4. Drug Interactions: Erythromycin is a potent inhibitor of the cytochrome P450 enzyme CYP3A4. This leads to numerous significant drug-drug interactions with medications metabolized by this pathway, including statins, warfarin, certain calcium channel blockers, and antiepileptic drugs. Managing these interactions can be complex and poses a safety risk, making physicians cautious about prescribing erythromycin stearate when potential interactions exist [6].

5. Regulatory Scrutiny and Stewardship Programs: Antimicrobial stewardship programs, promoted by regulatory bodies and healthcare organizations, encourage the judicious use of antibiotics. These programs often prioritize newer, more targeted agents and discourage the use of older antibiotics with broader resistance concerns or less favorable safety profiles for empirical treatment. Regulatory agencies also monitor antibiotic use patterns to combat resistance.

6. Limited Use in Severe Infections: Due to resistance concerns and the availability of more potent agents, erythromycin stearate is rarely the drug of choice for severe or life-threatening bacterial infections. Its utility is largely confined to outpatient settings for mild to moderate infections caused by susceptible organisms.

What is the Current Market Size and Projected Financial Trajectory?

The global market for erythromycin stearate is characteristic of a mature, genericized antibiotic. Precise, up-to-the-minute market size figures are difficult to pinpoint due to the highly fragmented nature of the generic drug market and varying reporting methodologies across regions. However, industry analysis suggests a stable to declining revenue trajectory.

Market Size Estimates: Based on available data and market trends for established macrolides, the global market for erythromycin stearate is estimated to be in the low hundreds of millions of U.S. dollars annually. This represents a small fraction of the overall antibiotic market, which is valued in the tens of billions of dollars. The volume of units sold remains significant due to its low price point, but the overall revenue contribution is constrained by pricing pressures and market share erosion.

Key Factors Influencing Financial Trajectory:

Price Erosion: Intense competition among generic manufacturers leads to continuous price erosion. This means that even if sales volumes remain stable, revenue will likely decline over time.
Competition from Newer Macrolides: Azithromycin and clarithromycin have largely displaced erythromycin in many common indications due to their superior profiles. This competition directly impacts erythromycin stearate's market share and revenue potential.
Antimicrobial Resistance Trends: As resistance to erythromycin grows, its clinical utility diminishes, leading physicians to opt for alternative treatments. This decline in empirical use directly reduces demand.
Healthcare Policy and Reimbursement: Changes in healthcare policies, formularies, and reimbursement rates can influence prescription patterns. Countries prioritizing cost-effective generics may maintain some demand, while those focusing on advanced therapies might see a faster decline.
Geographic Variations: The market trajectory will vary by region. Developed markets with advanced healthcare systems and widespread access to newer antibiotics are likely to see a sharper decline. Emerging markets, where cost is a more significant factor, may retain a more stable, albeit small, market share for erythromycin stearate for a longer period.

Projected Financial Trajectory: The financial trajectory for erythromycin stearate is projected to be flat to slightly declining globally over the next five to ten years. Growth is not anticipated. The key drivers for this projection are:

Stabilizing Demand in Niche Markets: Demand will likely stabilize in specific indications or geographic regions where cost-effectiveness remains paramount and resistance patterns do not preclude its use.
Continued Erosion in Developed Markets: In North America and Western Europe, the drug's use will likely continue to decrease as newer agents and stricter antimicrobial stewardship dominate.
Focus on Generics: Manufacturers will focus on optimizing production costs to remain competitive in the generic space. Profit margins will remain thin.
Limited R&D Investment: There is minimal incentive for significant research and development investment in erythromycin stearate itself, given its mature status and the availability of superior alternatives.

Table 1: Comparative Market Positioning of Macrolides

Antibiotic	Year of Introduction	Key Advantages	Key Disadvantages	Market Status
Erythromycin	1952	Historically significant, broad spectrum (Gram-positive)	GI side effects, drug interactions, significant resistance	Mature, Declining
Erythromycin Stearate	1959	Improved GI tolerance over base erythromycin, stable prodrug	Same as Erythromycin (resistance, interactions)	Mature, Declining
Clarithromycin	1990	Improved acid stability, better GI tolerance, broader spectrum	Drug interactions (CYP3A4), emerging resistance	Mature, Stable
Azithromycin	1988	Excellent GI tolerance, long half-life (once-daily dosing), broad spectrum	Increasing resistance, specific drug interactions (QT prolongation)	Mature, Stable

What is the Competitive Landscape for Erythromycin Stearate?

The competitive landscape for erythromycin stearate is characterized by a large number of generic manufacturers. The market is highly fragmented, with global players and regional suppliers vying for market share.

Key Players (Generic Manufacturers):

Teva Pharmaceuticals: A major global generic pharmaceutical company with a broad portfolio including antibiotics.
Viatris (formerly Mylan and Upjohn): Another significant player with a strong presence in generic drug markets worldwide.
Sun Pharmaceutical Industries: An Indian multinational pharmaceutical company that is a major producer of generics.
Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company with a substantial generics business.
Aurobindo Pharma: An Indian multinational pharmaceutical company focused on active pharmaceutical ingredients (APIs) and generic formulations.
Cipla: An Indian multinational pharmaceutical company with a wide range of generic medicines.

These companies compete primarily on price and reliable supply. The barriers to entry for manufacturing erythromycin stearate are low, given the well-established processes and availability of raw materials.

Factors influencing competition:

Cost of Goods Sold (COGS): Efficient manufacturing, sourcing of raw materials (erythromycin base and stearic acid), and economies of scale are critical for competitive pricing.
Supply Chain Reliability: Ensuring consistent availability of the drug to meet demand is essential. Disruptions can lead to lost market share.
Regulatory Compliance: Manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and regulatory requirements in all target markets.
Distribution Networks: Established relationships with wholesalers, distributors, and retail pharmacies are vital for market access.

The competition is intense, leading to thin profit margins for individual products. Companies that can achieve high production volumes and optimize their supply chains are best positioned to succeed in this segment of the pharmaceutical market.

What are the Future Outlook and Potential Opportunities?

The future outlook for erythromycin stearate is one of managed decline in developed markets, with pockets of stable demand in specific regions and applications. Significant growth is unlikely. However, limited opportunities may exist:

1. Cost-Sensitive Emerging Markets: In countries with developing healthcare infrastructure and where cost is a primary driver for antibiotic selection, erythromycin stearate may retain its market share for longer. Manufacturers with strong distribution networks in these regions could see sustained, albeit modest, sales volumes.

2. Specific Niche Indications: While less common, there may be rare or highly specific indications where erythromycin stearate remains a preferred agent due to lack of alternatives or unique efficacy against certain resistant strains that have not yet developed resistance to erythromycin itself. Identifying and focusing on these niches could provide marginal benefits.

3. API Manufacturing: For Active Pharmaceutical Ingredient (API) manufacturers, there is a continuous demand for erythromycin base, which is then converted to its stearate ester form. As long as there is a global demand for erythromycin stearate formulations, the underlying API will be required. Companies specializing in cost-effective, high-quality API production could find sustained business.

4. Synergistic Combinations (Limited): While not a current trend for erythromycin stearate, historically, macrolides have been explored in combination therapies to overcome resistance. However, given the emergence of resistance to erythromycin itself, and the availability of newer macrolides for combination studies, significant investment in this area for erythromycin stearate is improbable.

5. Public Health Initiatives: In the context of global health emergencies or specific public health campaigns targeting certain bacterial infections where erythromycin has a role, there could be temporary increases in demand. However, these are speculative and would likely be short-lived.

Overall, the future outlook for erythromycin stearate is characterized by its role as a low-cost, older antibiotic in a market increasingly dominated by newer, more effective, and often more expensive alternatives. Strategic focus for manufacturers will be on cost optimization, efficient production, and targeted distribution in regions where its cost-effectiveness remains a primary driver.

Key Takeaways

Erythromycin stearate is a mature, generic antibiotic facing significant competition from newer macrolides and other antibiotic classes.
Market drivers include its cost-effectiveness and persistent demand for certain common bacterial infections, particularly in emerging markets.
Major restraints are increasing antibiotic resistance, the availability of superior alternatives, gastrointestinal side effects, and complex drug interactions.
The global market size is estimated to be in the low hundreds of millions of U.S. dollars annually, with a projected flat to slightly declining financial trajectory.
The competitive landscape is dominated by generic manufacturers competing primarily on price.
Limited future opportunities exist, primarily in cost-sensitive emerging markets and specific niche indications.

Frequently Asked Questions

What is the primary reason for the decline in erythromycin stearate's market share? The primary reason is the significant increase in antibiotic resistance among common bacterial pathogens, coupled with the availability of newer macrolides (azithromycin, clarithromycin) and alternative antibiotic classes that offer improved efficacy, safety profiles, and pharmacokinetic advantages.
Are there any new therapeutic uses being explored for erythromycin stearate? No significant new therapeutic uses are being explored for erythromycin stearate. Its established applications are well-defined, and research and development efforts in antibiotics are focused on novel mechanisms of action and drugs to combat resistant pathogens.
How does erythromycin stearate's drug interaction profile compare to azithromycin and clarithromycin? Erythromycin stearate, like erythromycin base, is a potent inhibitor of CYP3A4, leading to numerous significant drug interactions. Clarithromycin also inhibits CYP3A4, though generally to a lesser extent than erythromycin. Azithromycin has a much weaker effect on CYP3A4 and thus has fewer clinically significant drug interactions compared to erythromycin and clarithromycin.
What are the typical price ranges for erythromycin stearate generic formulations? Generic formulations of erythromycin stearate typically range from $0.10 to $0.50 per unit (tablet or capsule), depending on the strength, dosage form, and region. This low price point is a key factor in its continued, albeit limited, use.
Can erythromycin stearate still be considered a first-line treatment for any common infections? In most developed countries, erythromycin stearate is generally not considered a first-line treatment for common infections due to resistance concerns and the availability of better alternatives. It may be considered a second-line option or used in specific situations where susceptibility is confirmed, cost is a major factor, or contraindications exist for other agents. Its use as first-line is more likely in regions with limited access to newer antibiotics.

Citations

[1] National Institute for Health and Care Excellence (NICE). (2023). Antibiotics for common infections: NICE guideline [NG230]. Retrieved from https://www.nice.org.uk/guidance/ng230 (Note: While NICE guidelines focus on recommendations, they reflect market availability and pricing considerations indirectly.)

[2] Infectious Diseases Society of America (IDSA). (Various years). Clinical Practice Guidelines. (Specific guidelines vary by infection, e.g., Community-Acquired Pneumonia, Skin and Soft Tissue Infections). (Note: IDSA guidelines inform treatment choices and reflect current understanding of resistance patterns and drug utility.)

[3] American Academy of Pediatrics. (2022). Red Book: Report of the Committee on Infectious Diseases. American Academy of Pediatrics.

[4] Davies, J., & Spiegel, C. A. (2014). Macrolide resistance mechanisms. Current Opinion in Microbiology, 18, 112-118.

[5] World Health Organization (WHO). (2021). Antibiotic resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance

[6] Lexicomp. (n.d.). Erythromycin: Drug Interactions. Retrieved from (Specific Lexicomp database access required for definitive content). (Note: Standard pharmacological databases like Lexicomp, Micromedex, or UpToDate are primary sources for drug interaction information.)

US Patents:	0
Tradenames:	8
Applicants:	12
NDAs:	15
Drug Master File Entries:	18
Raw Ingredient (Bulk) Api Vendors:	128
Clinical Trials:	1
Drug Prices:	Drug price trends for ERYTHROMYCIN STEARATE
What excipients (inactive ingredients) are in ERYTHROMYCIN STEARATE?	ERYTHROMYCIN STEARATE excipients list
DailyMed Link:	ERYTHROMYCIN STEARATE at DailyMed

ERYTHROMYCIN STEARATE - Generic Drug Details

What are the generic drug sources for erythromycin stearate and what is the scope of freedom to operate?

Summary for ERYTHROMYCIN STEARATE

Recent Clinical Trials for ERYTHROMYCIN STEARATE

Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN STEARATE

US Patents and Regulatory Information for ERYTHROMYCIN STEARATE

Erythromycin Stearate Market Dynamics and Financial Trajectory